China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has obtained approval from the National Medical Products Administration (NMPA) for its JP-1366 injection to conduct clinical studies in the treatment of peptic ulcer bleeding. This is a significant step forward for the company in the field of gastrointestinal therapeutics.
About JP-1366
JP-1366 is a novel potassium-competitive acid blocker (P-CAB). It functions by competitively binding to the potassium binding sites of H+/K+-ATPase in gastric wall cells, thereby inhibiting gastric acid secretion. The drug is currently under Phase III study for reflux esophagitis.
Market Context in China
At present, there is no approved injectable P-CAB product in China. Although four oral tablet versions of P-CAB are available in the country, the approval of JP-1366 injection for clinical study in peptic ulcer bleeding opens up new possibilities for the treatment of this condition and has the potential to fill a gap in the market.-Fineline Info & Tech
